Exenatide vs semaglutide efficacy
Pro Research Analysisby 
Searched over 200M research papers
Glycemic Control Efficacy: Semaglutide vs Exenatide ER in Type 2 Diabetes
Multiple studies directly comparing once-weekly semaglutide and exenatide extended-release (ER) in patients with type 2 diabetes consistently show that semaglutide provides greater reductions in HbA1c. In a large 56-week randomized trial, semaglutide 1.0 mg reduced HbA1c by 1.5%, compared to a 0.9% reduction with exenatide ER 2.0 mg, with a statistically significant difference favoring semaglutide Ahmann2017Bekiari2018. Additionally, a higher proportion of patients achieved the target HbA1c of less than 7.0% with semaglutide (67%) than with exenatide ER (40%) Ahmann2017Bekiari2018. Reviews and meta-analyses confirm these findings, consistently ranking semaglutide as more effective for glycemic control than exenatide ER Gæde2019Heimbürger2019.
Weight Loss Outcomes: Semaglutide Superiority
Semaglutide also leads to greater weight loss compared to exenatide ER. In the same head-to-head trial, patients on semaglutide lost an average of 5.6 kg, while those on exenatide ER lost 1.9 kg Ahmann2017Bekiari2018. This superior weight reduction with semaglutide is supported by systematic reviews and cost-effectiveness analyses, which highlight semaglutide’s advantage in helping patients reach both glycemic and weight loss targets Gæde2019Heimbürger2019Johansen2020+2 MORE.
Safety and Tolerability: Adverse Events Profile
Both semaglutide and exenatide ER have similar overall safety profiles, but there are differences in specific side effects. Gastrointestinal adverse events (such as nausea and vomiting) are more common with semaglutide (about 42%) than with exenatide ER (about 33%) Ahmann2017Bekiari2018. Conversely, injection-site reactions are more frequent with exenatide ER . Serious adverse events and treatment discontinuation rates are slightly higher with semaglutide, but both drugs are generally well tolerated Bekiari2018Heimbürger2019.
Cardiovascular Outcomes: Comparative Insights
Network meta-analyses suggest that semaglutide may have a higher probability of reducing major cardiovascular events, such as myocardial infarction and stroke, compared to exenatide ER, although direct differences are not always statistically significant Alfayez2020Heimbürger2019. Semaglutide is often ranked as the preferred agent for patients with diabetes and cardiovascular risk, while exenatide ER does not show the same level of cardiovascular benefit Alfayez2020Heimbürger2019.
Cost-Effectiveness and Real-World Adherence
Cost-effectiveness analyses in both European and US settings show that semaglutide offers better value for money than exenatide ER, due to its higher efficacy in achieving glycemic and weight loss targets at similar or lower costs per patient reaching these goals Gæde2019Johansen2020Johansen2019+1 MORE. Real-world data also indicate that patients are more likely to persist with and adhere to semaglutide treatment compared to exenatide ER .
Conclusion
In summary, semaglutide is more effective than exenatide ER for lowering HbA1c and promoting weight loss in patients with type 2 diabetes. While both drugs have similar safety profiles, semaglutide is associated with more gastrointestinal side effects but fewer injection-site reactions. Semaglutide may also offer greater cardiovascular benefits and is more cost-effective and better adhered to in real-world practice. For most patients, semaglutide represents a superior choice for glycemic and weight management compared to exenatide ER Ahmann2017Bekiari2018Alfayez2020+6 MORE.
Sources and full results
Most relevant research papers on this topic